Jabil Inc. (NYSE:JBL) is one of Jim Cramer’s Hottest GLP-1 and Weight Loss Stock Picks.

Jabil Inc. (NYSE:JBL) is one of the largest and most diversified contract manufacturing firms in the world. It is a key player in the weight loss drug industry due to its ability to manufacture the injector pens used to deliver the medicine. Jabil Inc. (NYSE:JBL)’s shares are up by a whopping 91% over the past year and by 47% since Cramer discussed the firm in June. The stock closed 6.7% lower on September 25th after the firm posted its fiscal fourth quarter earnings report. During the quarter, Jabil Inc. (NYSE:JBL)’s healthcare revenue grew by 4%, and weaknesses in other businesses meant that the growth in the firm’s AI business was insufficient to generate tailwinds for the stock. The weak performance came even though Jabil Inc. (NYSE:JBL)’s fourth quarter revenue of $8.3 billion beat analyst estimates. Year to date, the stock is up by 8.6%. Year to date, the stock is up by 8.6%. In March, the firm’s second-quarter earnings saw it post $8.3 billion in revenue and $2.69 in core earnings per share to surpass analyst estimates. Cramer was quite optimistic about Jabil Inc. (NYSE:JBL) in a June appearance on Mad Money:

“Jabil is so terrific that even though it’s up on a spike… I am again going to bless it. Why? Because it only sells at 22 times earnings, and it’s the kind of company you need to deal with right now. They’ll understand all the tariff problems and they’ll help you.”

While we acknowledge the potential of JBL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.